Insider Trading Alert - IMPV, AGCO, FCX, VRX And AME Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 8, 2013, 143 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $296.78 to $400,200,000.00.

Highlighted Stocks Traded by Insiders:

Imperva (IMPV) - FREE Research Report

Shulman Amichai who is Chief Technology Officer at Imperva sold 33,750 shares at $43.72 on Nov. 8, 2013. Following this transaction, the Chief Technology Officer owned 129,140 shares meaning that the stake was reduced by 20.72% with the 33,750 share transaction.

The shares most recently traded at $40.53, down $3.19, or 7.86% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 24-Week # shares sold: 750

The average volume for Imperva has been 308,700 shares per day over the past 30 days. Imperva has a market cap of $1.0 billion and is part of the technology sector and computer software & services industry. Shares are up 33.3% year to date as of the close of trading on Friday.

Imperva, Inc. engages in the development, marketing, sale, service, and support of business security solutions that provide visibility and control over high value business data across critical systems within the data center. The company operates in two segments, Imperva and Incapsula. Currently there are 5 analysts that rate Imperva a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings rates Imperva as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Imperva Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

AGCO (AGCO) - FREE Research Report

Srinivasan Mallika who is Director at AGCO bought 262,385 shares at $57.62 on Nov. 8, 2013. Following this transaction, the Director owned 1.7 million shares meaning that the stake was reduced by 18.68% with the 262,385 share transaction.

The shares most recently traded at $56.77, down $0.85, or 1.5% since the insider transaction. Historical insider transactions for AGCO go as follows:

  • 4-Week # shares sold: 2,606
  • 12-Week # shares sold: 5,212
  • 24-Week # shares sold: 32,820

The average volume for AGCO has been 1.1 million shares per day over the past 30 days. AGCO has a market cap of $5.6 billion and is part of the industrial goods sector and industrial industry. Shares are up 17% year to date as of the close of trading on Friday.

AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The stock currently has a dividend yield of 0.7%. The company has a P/E ratio of 10.2. Currently there are 5 analysts that rate AGCO a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGCO - FREE

TheStreet Quant Ratings rates AGCO as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, attractive valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AGCO Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Freeport-McMoRan Copper & Gold (FCX) - FREE Research Report

Johnston J Bennett who is Advisory Director at Freeport-McMoRan Copper & Gold bought 20,000 shares at $36.72 on Nov. 8, 2013. Following this transaction, the Advisory Director owned 140,085 shares meaning that the stake was reduced by 16.65% with the 20,000 share transaction.

The shares most recently traded at $36.24, down $0.48, or 1.33% since the insider transaction. Historical insider transactions for Freeport-McMoRan Copper & Gold go as follows:

  • 4-Week # shares bought: 18,900
  • 12-Week # shares bought: 18,900
  • 24-Week # shares bought: 18,900

The average volume for Freeport-McMoRan Copper & Gold has been 12.3 million shares per day over the past 30 days. Freeport-McMoRan Copper & Gold has a market cap of $37.3 billion and is part of the basic materials sector and metals & mining industry. Shares are up 5.06% year to date as of the close of trading on Friday.

Freeport-McMoRan Copper & Gold Inc. engages in the exploration of mineral resource properties. The company primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, such as rhenium and magnetite. The stock currently has a dividend yield of 3.48%. The company has a P/E ratio of 13.1. Currently there are 12 analysts that rate Freeport-McMoRan Copper & Gold a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FCX - FREE

TheStreet Quant Ratings rates Freeport-McMoRan Copper & Gold as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Freeport-McMoRan Copper & Gold Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Farmer Ronald Harold who is Director at Valeant Pharmaceuticals International bought 1,500 shares at $107.98 on Nov. 8, 2013. Following this transaction, the Director owned 27,808 shares meaning that the stake was reduced by 5.7% with the 1,500 share transaction.

The shares most recently traded at $104.91, down $3.07, or 2.93% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 59,532
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 70,472
  • 24-Week # shares sold: 20,000

The average volume for Valeant Pharmaceuticals International has been 1.2 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $34.4 billion and is part of the health care sector and drugs industry. Shares are up 72.39% year to date as of the close of trading on Friday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Ametek (AME) - FREE Research Report

Varet Elizebeth R who is Director at Ametek sold 5,000 shares at $48.71 on Nov. 8, 2013. Following this transaction, the Director owned 332,299 shares meaning that the stake was reduced by 1.48% with the 5,000 share transaction.

The shares most recently traded at $48.42, down $0.29, or 0.61% since the insider transaction. Historical insider transactions for Ametek go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 23,000

The average volume for Ametek has been 1.8 million shares per day over the past 30 days. Ametek has a market cap of $11.7 billion and is part of the industrial goods sector and industrial industry. Shares are up 27.6% year to date as of the close of trading on Friday.

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. The company operates in two segments, Electronic Instruments Group and Electromechanical Group. The stock currently has a dividend yield of 0.5%. The company has a P/E ratio of 23.5. Currently there are 5 analysts that rate Ametek a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AME - FREE

TheStreet Quant Ratings rates Ametek as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ametek Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%